At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 234 enrolled
Drug / intervention
rituximab [Mabthera/Rituxan]drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-label Study of MabThera Maintenance Therapy Compared With no Further Therapy After a Brief Induction With Chemotherapy Plus MabThera on Failure-free Survival in Treatment-naïve Elderly Patients With Advanced Follicular Lymphoma
In Brief
A Phase 3 clinical trial evaluating rituximab [Mabthera/Rituxan] for Non-Hodgkin's Lymphoma. Completed, enrolled 234 participants across 45 sites.
Detailed Summary
This study will evaluate the efficacy and safety of brief induction therapy with a chemotherapeutic regimen containing MabThera, followed by either maintenance therapy with MabThera or no further therapy. The anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Hodgkin's Lymphoma
CountriesItaly
Collaborators--
Timeline
Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2004
First PostedJun 2010
Primary CompletionJul 2011
TodayJul 2026
First PostedJun 15, 2010
Enrollment StartJan 19, 2004
Primary CompletionJul 21, 2011
TodayJul 2, 2026
Enrollment to primary: 7.5 yearsPosted 16.0 years ago
Interventions
rituximab [Mabthera/Rituxan]drug
Intravenous repeating dose